期刊
CURRENT DIABETES REPORTS
卷 14, 期 12, 页码 553-U21出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11892-014-0553-6
关键词
Tolerance; Immunotherapy; Autoimmune disease; Inflammation; Pharmacokinetics
资金
- AP-HP
- UPMC
- INSERM
- Inflammation-Immunopathology- Biotherapy Department (DHU i2B)
- French state funds [ANR-11-IDEX-0004-02]
- DIABIL-2, part of the Seventh Framework Program collaborative project for type 1 diabetes [305380]
Regulatory T cells (Tregs) play a major role in controlling effector T cells (Teffs) responding to self-antigens, which cause autoimmune diseases. An improper Treg/Teff balance contributes to most autoimmune diseases, including type 1 diabetes (T1D). To restore a proper balance, blocking Teffs with immunosuppressants has been the only option, which was partly effective and too toxic. It now appears that expanding/activating Tregs with low-dose interleukin-2 (IL-2) could provide immunoregulation without immunosuppression. This is particularly interesting in T1D as Tregs from T1D patients are reported as dysfunctional and a relative deficiency in IL-2 production and/or IL-2-mediated signaling could contribute to this phenotype. A clinical study of low-dose IL-2 showed a very good safety profile and good Treg expansion/activation in T1D patients. This opens the way for efficacy trials to test low-dose IL-2 in prevention and treatment of T1D and to establish in which condition restoration of a proper Treg/Teff balance would be beneficial in the field of autoimmune and inflammatory diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据